Clinical Trial Update: A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BMS-188667 in relapsing-remitting multiple sclerosis. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BMS-188667

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED